Cannabis startup CannPal to list on ASX, targets $4.7m IPO

CannPal Animal Therapeutics, a Sydney-based pharmaceutical technology startup, is looking to raise A$6 million ($4.74 million) in its initial public offer (IPO) on the Australian Securities Exchange (ASX) slated for October 2017.

CannPal has successfully lodged a prospectus with the Australian Securities and Investments Commission (ASIC) and intends to issue 30 million shares at an issue price of A$0.20 per share. It forecasts an expected market capitalisation of A$18.5 million.

Founded and led by managing director Layton Mills, CannPal aims to develop cannabis-based veterinary products that can be administered as pain relief to companion animals. Mills is also the co-founder of Canberra-based natural health foods trader Tanlay Food Group.

Since inception in 2016, it has grown to a team of 13 but currently lacks revenue streams as it is focused on RD and clinical trials of its product.

The decision to list on the ASX stems from its

... read more at: